Anest. intenziv. Med. 2006;17(6):287-294

Physostigmine and its place in modern anaesthesiology and intensive careAnaesthesiology - Comprehensive Report

L. Hess1, J. Málek2, J. Schreiberová3
1 Centrum experimentální medicíny, IKEM Praha
2 Klinika anesteziologie a resuscitace 3. LF UK a FNKV, Praha
3 Klinika anesteziologie, resuscitace a intenzivní medicíny, FN Hradec Králové

Physostigmine was isolated from Calabar (ordeal) beans in 1864 and used for glaucoma therapy. Nowadays its main indication is the treatment of the central anticholinergic syndrome which is a relatively common complication of general anaesthesia and analgesic sedation in the ICU. The pharmacokinetic and pharmacodynamic properties and interactions of physostigmine with drugs commonly used in anaesthesia (volatile anaesthetics, propofol, benzodiazepines, opioides and dehydrobenzperidole) are described. A short review of the central anticholinergic syndrome symptoms and therapy is presented. Physostigmine effects on ethyl alcohol intoxication, muscle shivering and Alzheimer's disease are also mentioned.

Keywords: physostigmine; history; pharmacology; central anticholinergic syndrome

Published: December 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hess L, Málek J, Schreiberová J. Physostigmine and its place in modern anaesthesiology and intensive care. Anest. intenziv. Med. 2006;17(6):287-294.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dworacek, B., Rupreht, J. Physostigmine: Short history and its impact on anaesthesiology. In Diz, J. C. et al., ed. The history of Anaesthesia. Elsevier 2002, p. 87-93. Go to original source...
    2. Dvořáček, B. CAS - fyzostigmin a česká anesteziologie. Anest. intenziv. Med., 2003, 14, s. 139-141.
    3. Kleinwächter, L. Beobachtung über die Wirkung des Calabarextracts gegen Atropin-Vergiftung. Berliner klinische Wochenschrift, 1864, 1, 38, s. 369-371.
    4. Patočka J. Fyzostigmin: lék, který významným způsobem ovlivnil medicínu. Kontakt, 2004, 6, s. 224-229.
    5. Rupreht, J., Dworacek, B. The central anticholinergic syndrome in the postoperative period. In Prys-Roberts, C. et al., ed. Internationale practice of anaesthesia. Oxford : Butterworth-Heinemann, 132, p. 1-11.
    6. Rupreht, J., Dworacek, B. Central anticholinergic syndrome during postoperative period. Ann. Fr. Anesth. Reanim., 1990, 9, s. 295-304. Go to original source... Go to PubMed...
    7. Katsanoulas, K., Papaioannou, A., Fraidakis, O., Michaloudis, D. Undiagnosed central anticholinergic syndrome may lead to dangerous complications. Eur. J. Anaesthesiol., 1999, 16, p. 803-809. Go to original source... Go to PubMed...
    8. Link, J., Papadopoulos, G., Dopjans, D., Guggenmoos-Holzmann, I., Eyrich, K. Distinct central anticholinergic syndrome following general anaesthesia. Eur. J. Anaesthesiol., 1997, 14, p. 15-23. Go to original source... Go to PubMed...
    9. Schneck, H. J., von Hundelshausen, B., Tempel, G., Brosch, R. Modification of vigilance in the postanesthetic phase using physostigmine. Anaesthesist, 1985, 34, p. 456-461. Go to PubMed...
    10. Latasch, L., Muller, B., Freye, E. Postoperative routine use of physostigmine on vigilance, cardiovascular parameters and need of analgesics. Anasthesiol. Intensivmed. Notfallmed. Schmerzther., 2003, 38, p. 528-537. Go to PubMed...
    11. Rupreht, J., Valkenburg, M., Dworacek, B., Osthoek, H. Physostigmin versus naloxone in heroin overdose. Clin. Toxicol., 1984, 21, p. 387-397. Go to original source... Go to PubMed...
    12. Weinstock, M., Roll, D., Erez, E., Bahar, M. Physostigmine antagonizes morphine-induced respiratory depression but not analgesia in dogs and rabbits. Br. J. Anaesth., 1980, 52, p. 1171-1176. Go to original source... Go to PubMed...
    13. Weinstock, M., Davidson, J. T., Rosin, A. J., Schnieden, H. Effect of physostigmine on morphine-induced postoperative pain and somnolence. Br. J. Anaesth., 1982, 54, p. 429-434. Go to original source... Go to PubMed...
    14. Beilin, B., Bessler, H., Papismedov, L., Weinstock, M., Shavit, Y. Continuous physostigmine combined with morphine-based patient-controlled analgesia in the postoperative period. Acta Anaesthesiol. Scand., 2005, 49, p. 78-84. Go to original source... Go to PubMed...
    15. Plourde, G., Chartrand, D., Fiset, P., Font, S., Backman, S. B. Antagonism of sevoflurane anaesthesia by physostigmine: effects on the auditory steady-state response and bispectral index. Br. J. Anaesth., 2003, 91, p. 583-586. Go to original source... Go to PubMed...
    16. Bidwai, A. V., Cornelius, L. R., Stanley,T. H. Reversal of Innovar-induced postanesthetic somnolence and disorientation with physostigmine. Anesthesiology, 1976, 44, p. 249-252. Go to original source... Go to PubMed...
    17. Ebert, U., Oertel, R., Kirch, W. Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects. Clin. Pharmacol. Ther., 2000, 67, p. 538-548. Go to original source... Go to PubMed...
    18. Bidwai, A. V., Stanley, T. H., Rogers, C., Riet, E. K. Reversal of diazepam-induced postanesthetic somnolence with physostigmine. Anesthesiology, 1979, 51, p. 256-259. Go to original source... Go to PubMed...
    19. Kubota, T., Hirota, K., Anzawa, N., Yoshida, H., Kushikata, T., Matsuki, A. Physostigmine antagonizes ketamine-induced noradrenaline release from the medial prefrontal cortex in rats. Brain Res., 1999, 840, p. 175-178. Go to original source... Go to PubMed...
    20. Hamilton-Davies, C., Bailie, R., Restall, J. Physostigmine in recovery from anaesthesia. Anaesthesia, 1995, 50, p. 456-458. Go to original source... Go to PubMed...
    21. Engelhardt, W., Stahl, K., Marouche, A., Hartung, E., Dierks, T. Ketamine racemate versus S-(+)-ketamine with or without antagonism with physostigmine. A quantitative EEG study on volunteers. Anaesthesist, 1994, 43, Suppl 2, S76-82. Go to PubMed...
    22. Meuret, P., Backman, S. B., Bonhomme, V., Plourde, G., Fiset, P. Physostigmine reverses propofol-induced unconsciousness and attenuation of the auditory steady state response and bispectral index in human volunteers. Anesthesiology, 2000, 93, p. 708-717. Go to original source... Go to PubMed...
    23. Fassoulaki, A., Sarantopoulos, C., Derveniotis, C. Physostigmine increases the dose of propofol required to induce anaesthesia. Can. J. Anaesth., 1997, 44, p. 1148-1151. Go to original source... Go to PubMed...
    24. Málek J. Centrální anticholinergní syndrom. In Jiránek, P., ed. Sborník přednášek a abstrakt III. anesteziologické dny Vysočiny. Jihlava : MSM 2004, s. 101-102.
    25. Snir-Mor, I., Weinstock, M., Davidson, J. T., Bahar, M. Physostigmine antagonizes morphine-induced respiratory depression in human subjects. Anesthesiology, 1983, 59, p. 6-9. Go to original source... Go to PubMed...
    26. Berkenbosch, A., Olievier, C. N., Wolsink, J. G., DeGoede, J., Rupreht, J. Effects of morphine and physostigmine on the ventilatory response to carbon dioxide. Anesthesiology, 1994, 80, p. 1303-1310. Go to original source... Go to PubMed...
    27. Petersson, J., Gordh, T. E., Hartvig, P., Wiklund, L. A double-blind trial of the analgesic properties of physostigmine in postoperative patients. Acta Anaesthesiol. Scand., 1986, 30, p. 283-288. Go to original source... Go to PubMed...
    28. Horn, E. P., Standl, T., Sessler, D. I., von Knobelsdorff, G., Buchs, C. et al. Physostigmine prevents postanesthetic shivering as does meperidine or clonidine. Anesthesiology, 1998, 88, p. 108-113. Go to original source... Go to PubMed...
    29. Kleinschmidt, S., Ziegeler, S., Bauer, C. Cholinesterase inhibitors. Importance in anaesthesia, intensive care medicine, emergency medicine and pain therapy. Anaesthesist, 2005, 54, p. 791-799. Go to original source... Go to PubMed...
    30. Liston, D. R., Nielsen, J. A., Villalobos, A. et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur. J. Pharmacol., 2004, 486, p. 9-17. Go to original source... Go to PubMed...
    31. Coelho, F., Birks, J. Physostigmine for Alzheimer's disease. Cochrane Database Syst. Rev., 2001, CD001499.

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.